1. HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. (December 2021) Authors: Ho, Cassandra S.L.; Tüns, Alicia I.; Schildhaus, Hans-Ulrich; Wiesweg, Marcel; Grüner, Barbara M.; Hegedus, Balazs; Schuler, Martin; Schramm, Alexander; Oeck, Sebastian Journal: European journal of cancer Issue: Volume 159(2021) Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗